$18.45
Value $1.4B
INVA and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$18.45
Value $1.4B
$132.59
Value $328B
Innoviva (INVA) has a market value of $1.4B and Merck & Company (MRK) $328B. Over the last year, with dividends, INVA moved -15.7% and MRK +41.6%. The P/E is 7.1 for INVA and 133.6 for MRK. Dividend yield: INVA none, MRK 2.56%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
INVA$1.4B
MRK$328B
MRK is 240 times INVA
Revenue, 12 months
INVA$438M
MRK$67.4B
MRK is 154 times INVA
Net income, 12 months
INVA$193M
MRK$2.5B
MRK is 13 times INVA
Operating margin
INVA38.8%
MRK–
ROIC
INVA9.5%
MRK3.9%
5.6 points apart
P/E
INVA7.1
MRK133.6
MRK is 19 times INVA
Dividend yield
INVA0.0%
MRK2.6%
2.6 points apart
5-year return
INVA+7.6%
MRK+86.0%
78.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
INVA+7.6%
MRK+86.0%
| Period | INVAWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | -15.7%Price -15.7% | +41.6%Price +37.5% |
| 3 years since November 17, 2023 | +34.4%+10.4% a yearPrice +34.4% | +42.8%+12.6% a yearPrice +30.3% |
| 5 years since November 18, 2021 | +7.6%+1.5% a yearPrice +7.6% | +86.0%+13.2% a yearPrice +59.7% |
| 10 years since November 21, 2016 | +68.9%+5.4% a yearPrice +68.9% | +202.6%+11.7% a yearPrice +123.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
INVAInnovivaMRKMerck & Company
| Price | $18.45 | $132.59 |
|---|---|---|
| Market value | $1.4B | $328B |
| Enterprise value (EV) | $1.0B | $372B |
| P/E | 7.1 | 133.6 |
| P/E, 5-year median | 6.1 | 14.8 |
| P/B | 1.2 | 7.3 |
| EV/EBIT | 6.1 | 78.1 |
| Free cash flow yield | 13.4% | 4.5% |
| Revenue, 12 months | $438M | $67.4B |
|---|---|---|
| Net income, 12 months | $193M | $2.5B |
| Free cash flow, 12 months | $183M | $14.7B |
| Earnings per share, 12 months | $2.61 | $0.98 |
| Revenue growth, year on year | 14.7% | 1.3% |
| Revenue growth a year, past | +4.1%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | +10.3%over 5 years | +21.2%over 5 years |
| Gross margin | 74.5% | 71.8% |
|---|---|---|
| Operating margin | 38.8% | – |
| Net margin | 44.1% | 3.6% |
| ROIC | 9.5% | 3.9% |
| ROE | 16.4% | 5.2% |
| Cash | $581M | $9.7B |
|---|---|---|
| Total debt | $270M | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | 8.6× | 2.4× |
| Dividend yield | – | 2.6% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 0.3% | 1.6% |
| Shareholder yield | 0.3% | 4.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($328B) is about 239.9 times Innoviva ($1.4B), at today's prices.
Since November 21, 2016, INVA's price moved +68.9% and MRK's +123.0%. With dividends: INVA +68.9% (+5.4% a year), MRK +202.6% (+11.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Innoviva and 2.56% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 7.1 for INVA and 133.6 for MRK. The median of the last five years was 6.1 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 44.1% for Innoviva and 3.6% for Merck & Company, and the operating margin 38.8% and –. Revenue was $438M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.